Key result
Circular RNAs exhibit ~2- to 5-fold longer half-lives than linear RNAs, regulating key cardiovascular pathways.
Why the study?
The growing prevalence of cardiovascular diseases creates an urgent need for novel diagnostic and therapeutic approaches, with circular RNAs emerging as potential biomarkers and therapeutic targets.
This review summarizes the biogenesis, molecular mechanisms, and functional roles of circular RNAs in cardiovascular diseases, highlighting their potential as novel biomarkers and therapeutic targets despite current translational challenges.
Answers are grounded in this paper and cite their sources.
CircRNAs merit continued preclinical investigation in cardiovascular disease; leaves open clinical translation as biomarkers or targets.
Cardiovascular diseases (CVDs) remain the leading cause of global mortality, accounting for approximately one-third of all deaths. The growing prevalence of CVDs underscores the urgent need for novel diagnostic and therapeutic approaches. Circular RNAs (circRNAs), a class of single-stranded RNA molecules formed through back-splicing, have attracted considerable attention as potential biomarkers and therapeutic targets due to their unique characteristics. Unlike linear RNAs, circRNAs lack free 3′ and 5′ ends, making them highly resistant to exonuclease degradation and thereby markedly more stable, with a half-life approximately 2–5 times longer than that of linear RNAs. Their stability, tissue- and disease-specific expression patterns, evolutionary conservation, and responsiveness to pathological stimuli enable them to regulate key biological processes such as apoptosis, metabolism, and inflammation. Growing evidence suggests that circRNAs play a role in the pathogenesis of CVDs: circRNA expression levels differ between cardiac tissues of healthy individuals and those of patients with various CVDs; in arterial hypertension, circRNAs 0037909 and 0037911 are closely associated with elevated blood pressure; following myocardial infarction, circRNA FoxO3 exacerbates myocardial injury, whereas circ-Amotl1 attenuates apoptosis and reduces adverse remodeling; in myocardial hypertrophy, knockdown of circSlc8a1 decreases hypertrophy, while circRNA 000203 promotes it by modulating hypertrophic gene expression; in heart failure, an inverse correlation between MICRA levels and left ventricular ejection fraction has been identified, making MICRA a valuable early indicator of left ventricular dysfunction. This review provides a detailed analysis of circRNAs in CVDs, including their biogenesis, molecular mechanisms, and functional roles. It also evaluates their potential as diagnostic and prognostic biomarkers, and discusses therapeutic advances based on circRNAs (synthetic circRNA sponges) and low-molecular-weight drugs. However, despite these promising findings, numerous challenges remain unresolved, including tissue-specific delivery of circRNAs and control of their complex pleiotropic effects. Furthermore, most data on the role of circRNAs, particularly in CVDs, have been obtained from preclinical studies, often involving animal models or in vitro systems. Therefore, further validation through comprehensive preclinical research and well-designed clinical trials is essential. Successful future integration of circRNA-based tools into clinical practice could fundamentally transform CVD management, enabling earlier detection and more personalized treatment strategies.
No takes yet. Share an insight, caveat, or question.
Айтбаев et al. (2026) conducted a review in Cardiovascular diseases. Circular RNAs (circRNAs) vs. Linear RNAs / healthy individuals was evaluated. Circular RNAs exhibit a half-life 2–5 times longer than linear RNAs and regulate apoptosis, metabolism, and inflammation in cardiovascular diseases.
Synapse has enriched 10 related papers. Consider them for comparative context: